The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
Medicare coverage for Wegovy expanded to include patients with established heart disease, and prescriptions have surged as a result. If you're on Medicare and managing cardiovascular risk, this shift could significantly change what you pay and what you can access. Here's what you need to know.
The ease of buying GLP-1 medications online has raised serious safety concerns, including overdose risks, counterfeit drugs, and unregulated dosing. This guide helps you understand the dangers and how to find a legitimate provider who will actually protect your health.
Maryland is moving to cap the out-of-pocket cost of Ozempic and other GLP-1 medications, starting with state employees now and expanding to all residents by 2028. This policy shift could reshape how patients access and afford semaglutide across the state. Here's what you need to know and how to prepare.
CVS has reversed course and added Eli Lilly's obesity medication back to its formulary, potentially restoring coverage for millions of members. This shift has real implications for your out-of-pocket costs and access to tirzepatide. Here is what patients need to know right now.
Millions of Americans on GLP-1 medications like semaglutide and tirzepatide are eating less and buying differently, and major retailers are starting to feel it. Learn what this shift means for your grocery habits, your nutrition needs, and how to make the most of your reduced appetite.
North Carolina's expected state budget will not restore GLP-1 weight-loss drug coverage for state employees, leaving thousands without insurance support for medications like Wegovy and Ozempic. This article breaks down what the coverage loss means financially, who is affected, and what practical steps you can take to manage costs or find alternatives.
Brazil has approved the first generic version of semaglutide, the active ingredient in Ozempic. While this approval does not immediately affect U.S. patients, it signals a major shift in the global GLP-1 landscape. Here's what it could mean for access and cost down the road.
The role of pharmacists in GLP-1 and peptide medicine is expanding fast, and that shift has real implications for how patients access, afford, and manage their medication. This article breaks down what the growing pharmacist role means for you, whether you're already on a GLP-1 or just starting to explore your options.
